Canada inks $56million deal with Bavarian Nordic (BAVA) for Monkeypox Vaccine

Be the First to Comment Read

Canada inks $56million deal with Bavarian Nordic (BAVA) for Monkeypox Vaccine

Danish biotech Bavarian Nordic has signed a $56 million contract with Canada for its smallpox vaccine, which is also approved for use against monkeypox. According to the company, it’s continuing “to secure contracts with other countries, including Denmark, but also countries outside Europe, to supply the vaccine to mitigate the current monkeypox outbreak". 

Disclaimer

Speak your Mind

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK